Company Research Report: Generate:Biomedicines

---

Company Overview

• Name: Generate:Biomedicines

• Mission: To harness the power of data and machine learning to program biology, creating novel therapeutics that are faster, better, and more effective for patients.

• Founded: 2018

• Founder: Flagship Pioneering

• Key People:

• Michael Nally - Chief Executive Officer

• Molly Gibson - Co-Founder

• Gevorg Grigoryan - Co-Founder & Chief Technology Officer

• Beth Grous - Chief People Officer

• Daria Hazuda - Head of Infectious Disease and Vaccines Research

• Sean Martin - Chief Legal Officer & General Counsel

• Jason Silvers - Chief Financial Officer

• Alex Snyder - Executive Vice President, Research & Development

• Alex Therien - Senior Vice President, Drug Design and Preclinical Development

• Kym White - Chief Corporate Affairs Officer

• Lisa Wyman - Chief Technical Operations Officer

• Headquarters: 101 South Street, Suite 900, Somerville, MA 02143, United States

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Advancing the field of generative biology to create breakthrough medicines through the Generate Platform, which combines machine learning, biological engineering, and medicine.

Products

• The Generate Platform:

• High-level Description: A platform that generates medicines across multiple therapeutic modalities using machine learning to analyze protein structures and sequences.

• Key Features:

• Rapid generation of protein therapeutics.

• Application across antibodies, peptides, enzymes, and stealth proteins.

• Pipeline Products:

• GB-0669:

• Description: AI-generated viral neutralizing antibody targeting the SARS-CoV-2 S2 domain.

• Key Features: Effective across variants and related coronaviruses, overcoming traditional biologics limitations.

• GB-0895:

• Description: Anti-TSLP treatment for asthma.

• Key Features: Completed Phase 1, potential as foundational therapy for future combinations.

• GB-7624:

• Description: Anti-IL-13 treatment targeting atopic dermatitis.

• Key Features: Preparing for Phase 1 trial in 2025.

• Various Preclinical Programs:

• Description: Diverse range of biologic and bispecific proteins for various indications.

• Key Features: Targeting diseases like severe asthma, ulcerative colitis, and cancer using novel protein complexes.

Recent Developments

• New Products and Features:

• Successful Phase 1 study of GB-0669, designed for long-lasting COVID-19 protection with positive results showing significant viral neutralization at high doses.

• Introduction of AI-driven drug platform to create differentiated molecules with precise characteristics.

• Partnerships:

• Collaboration with Novartis to discover and develop protein therapeutics, valued at over $1 billion, integrating generative AI with Novartis’ development capabilities.

• Platform Enhancements:

• Integrating machine learning and high-throughput experimentation to continuously advance platform capabilities.

• Recent technological advancements in CryoEM, multiplexed biological assays, and protein manufacturing.

• Healthcare Conference:

• Presentation by CEO Mike Nally at the J.P. Morgan Healthcare Conference outlining the platform’s capabilities and potential to tackle undruggable targets.

---

The information detailed in this report focuses on the company's strategies, technological approaches, and strategic partnerships aimed at revolutionizing drug discovery and development.